Vertero Therapeutics

Vertero Therapeutics is an early-stage biotech pioneering an unorthodox, gut-brain axis approach to treating neurodegenerative diseases like Parkinson's. Its lead candidate, VT-5006, is a pre-clinical oral therapeutic designed to modulate a peripheral target in the gut to address protein aggregation and inflammation driving brain pathology. The company is led by a seasoned team with deep drug discovery and development experience and is privately funded, positioning it to advance its novel pipeline.

A discovery and development platform focused on the gut-brain axis, designing oral therapeutics that precisely modulate peripheral targets (e.g., in the gut) known to drive protein aggregation and inflammation in the brain.

Competes in the crowded neurodegenerative disease space against both large pharma and biotechs. Differentiation lies in its specific focus on oral, gut-targeted therapies, a niche but growing area with fewer clinical-stage competitors than direct CNS-targeting approaches.